Dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy
Negative effect in the outcome category of side effects does not call into question positive effects in morbidity and health-related quality of life; indication of non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.
Project details
- Project no.
- A19-75
- Commission
- Commission awarded on 29.08.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75
Status: Commission completed
-
Dossier assessment
Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed